Metabolic syndrome Type 2 diabetes mellitus
Conditions
Interventions
MET treatment (1.4 V/cm, 0.1ms, 55 pps, 42 degrees for 60min), 4 times/week for 4weeks. Then 4weeks of no treatment.
First, 4 weeks of no treatment. Then, MET treatment (1.4 V/cm, 0.1ms, 55 pps, 42 de
Sponsors
Kumamoto University, Faculty of Life Sciences, Metabolic Medicine
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Metabolic syndrome (MS) Abdominal obesity, given as waist circumference greater than 85 cm with meets 2 criteria in 3 shown below, i)Triglycerides: greater than or equal to 150 mg/dL and/or HDL cholesterol: less than 40 mg/dL ii)Systolic Blood pressure: greater than or equal to130 mmHg and/or Diastolic blood pressure: greater than or equal to 85 mmHg iii)Fasting blood glucose: greater than or equal to 110 mg/dL Type 2 diabetes mellitus (T2DM) i)Abdominal obesity, given as waist circumference greater than 85 cm ii)HbA1c more than 6.9%, less than 9.5% (NGSP)
Exclusion criteria
Exclusion criteria: i) Past history or current medication of myocardial infarction, angina, apoplexy and arteriosclerosis obliterans. ii)Severe wound, infections, pre- or post-operation. iii)Severe liver dysfunction (GOT and/or GPT: greater than 100U). iv)Chronic heart failure, familial dyslipidemia. v)Severe diabetic complications. vi)HbA1c : greater than or equal to 6.9%. (only in MS) vii)Pacemaker carrier.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The expression of CRP, IL-6, NF-kB, TNF-a, HSP72 in monocytes. | — |
Countries
Japan
Contacts
Public ContactTatsuya Kondo
Kumamoto University, Faculty of Life Sciences Metabolic Medicine
Outcome results
None listed